VJHemOnc is committed to improving our service to you

ASH 2019 | Result of venetoclax plus/minus azacitidine for R/R MDS

VJHemOnc is committed to improving our service to you

Amer Zeidan

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the updated data from the ongoing phase 1b, open-label, multicenter study (NCT02966782) evaluating the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in relapsed/refractory myelodysplastic syndromes (MDS). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter